Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSS | P25774 | 2/20 | 0.60 |
| ▸ | KDM1A | O60341 | 2/20 | 0.56 |
| ▸ | LMNA | P02545 | 1/20 | 0.52 |
| ▸ | IDO1 | P14902 | 1/20 | 0.51 |
| ▸ | KMO | O15229 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.50 |
| ▸ | CCR1 | P32246 | 1/20 | 0.50 |
| ▸ | CCR8 | P51685 | 1/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.50 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.50 |
| ▸ | HPGD | P15428 | 1/20 | 0.50 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.50 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.50 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.50 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.50 |
| ▸ | GABRA2 | P47869 | 1/20 | 0.50 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.50 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17207482 | 0.88 | CCR1 (0.52) | CTSSKDM1ALMNAKMOCCR1 | |
| SCHEMBL2615265 | 0.82 | CCR1 (0.54) | CCR1CCR8CYP2A6 | |
| SCHEMBL2614939 | 0.82 | IDO1 (0.51) | CTSSKDM1AIDO1KMOALDH1A1 | |
| SCHEMBL18758860 | 0.82 | CYP2A6 (0.53) | CTSSKDM1ALMNAIDO1CCR1 | |
| SCHEMBL19865072 | 0.81 | KDM1A (0.62) | CTSSKDM1ALMNAIDO1KMO | |
| SCHEMBL11990860 | 0.81 | CCR1 (0.68) | CCR1CCR8CYP2A6 | |
| SCHEMBL4936538 | 0.81 | CCR1 (0.44) | CTSSKDM1ACCR1CCR8XDH | |
| SCHEMBL9971080 | 0.80 | CTSS (0.57) | CTSSKDM1ALMNAIDO1KMO | |
| SCHEMBL14616445 | 0.79 | CTSS (0.50) | CTSSKDM1ALMNAIDO1KMO | |
| SCHEMBL6256565 | 0.79 | CTSS (0.60) | CTSSKDM1ALMNAIDO1KMO |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8912218-B2 | Alkylthiazol carbamate derivatives, preparation thereof and therapeutic use thereof | SANOFI (FR) | 2014-12-16 | — | — | US | disclosed |
| US-8785445-B2 | 7-phenoxychroman carboxylic acid derivatives | ARRAY BIOPHARMA INC. (US) | 2014-07-22 | — | — | US | disclosed |
| US-20120101103-A1 | 7-PHENOXYCHROMAN CARBOXYLIC ACID DERIVATIVES | ARRAY BIOPHARMA INC. (US) | 2012-04-26 | — | — | US | disclosed |
| US-20110212963-A1 | ALKYLTHIAZOL CARBAMATE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF | SANOFI-AVENTIS (FR) | 2011-09-01 | — | — | US | disclosed |
| US-7582658-B2 | Bicyclic compound | ASAHI KASEI PHARMA CORPORATION (JP) | 2009-09-01 | — | — | US | disclosed |
| US-7582658-B2 | Bicyclic compound | ASAHI KASEI PHARMA CORPORATION (JP) | 2009-09-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110212963-A1 | ALKYLTHIAZOL CARBAMATE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF | MET, ALK, REL | CTSS 1439/4885KDM1A 1353/4885LMNA 3832/4885 |
| US-20120101103-A1 | 7-PHENOXYCHROMAN CARBOXYLIC ACID DERIVATIVES | PTGDR2, PTGDR, HRH2 | CTSS 2690/4885KDM1A 1205/4885LMNA 3384/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.